SCHEMBL30830585

SCHEMBL30830585

Cc1cc(OC2CCN(Cc3ccc([C@H]4C[C@@H](Nc5cnn(C)c(=O)c5Br)CN(C)C4)cc3)CC2)ccc1C1CCC(=O)NC1=O

nearest known ligand 0.48

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ KAT2B Q92831 17/20 0.48
▸ BRD9 Q9H8M2 3/20 0.48
▸ BRD1 O95696 1/20 0.48
▸ ACHE P22303 1/20 0.48
▸ BRPF1 P55201 1/20 0.48
▸ BPTF Q12830 1/20 0.48
▸ KAT2A Q92830 1/20 0.48
▸ BRD7 Q9NPI1 1/20 0.48
▸ BAZ2B Q9UIF8 1/20 0.48
▸ BRPF3 Q9ULD4 1/20 0.48
▸ DDB1 Q16531 2/20 0.36
▸ CRBN Q96SW2 2/20 0.36
▸ IKZF2 Q9UKS7 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30830479 0.95 KAT2B (0.48) KAT2BBRD9BRD1ACHEBRPF1
SCHEMBL30830696 0.92 KAT2B (0.48) KAT2BBRD9BRD1ACHEBRPF1
SCHEMBL30831057 0.92 KAT2B (0.53) KAT2BBRD9BRD1ACHEBRPF1
SCHEMBL30830886 0.91 KAT2B (0.53) KAT2BBRD9BRD1ACHEBRPF1
SCHEMBL30830652 0.88 KAT2B (0.48) KAT2BBRD9BRD1ACHEBRPF1
SCHEMBL30830874 0.87 KAT2B (0.47) KAT2BBRD9BRD1ACHEBRPF1
SCHEMBL30830829 0.86 KAT2B (0.54) KAT2BBRD9BRD1ACHEBRPF1
SCHEMBL30830583 0.86 KAT2B (0.57) KAT2BBRD9BRD1ACHEBRPF1
SCHEMBL30830817 0.86 KAT2B (0.54) KAT2BBRD9BRD1ACHEBRPF1
SCHEMBL30830677 0.86 KAT2B (0.44) KAT2BBRD9BRD1ACHEBRPF1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4581025-A1 PYRIDAZINON DERIVATIVES AS KAT2 DEGRADERS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS Auron Therapeutics, Inc. (US) 2025-07-09 — — EP disclosed
WO-2024050078-A1 PYRIDAZINON DERIVATIVES AS KAT2 DEGRADERS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS AURON THERAPEUTICS, INC. (US) 2024-03-07 — — WO disclosed
Send feedback